Total: $153.903M | ||||
Company |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; Placement Agents; Details |
| | ||||
Aphton Corp. (APHT) |
Private placement of common stock |
0.5S and |
$1.52 |
Aphton sold 500,000 shares of common stock from its shelf registration statement raising $1.5M, and it sold 150,000 warrants for $18,750 (2/24) |
|
|
|||
|
Aradigm Corp. (ARDM)
|
Private placement of common stock and warrants |
19S and |
$15 |
Aradigm raised $15M in a private placement of 19M shares and warrants to purchase about 4.3M shares (2/12) |
|
||||
Cepheid Inc. (CPHD) |
Private placement of common stock |
1.4S |
$5 |
Cepheid raised $5M in a private placement of stock; EHS Securities LLC acted as exclusive selling agent for the offering (2/28) |
|
||||
Hollis-Eden Pharmaceuticals Inc. (HEPH) |
Private placement of convertible debentures |
N/A |
$10 |
Hollis-Eden raised $10M through the private placement of debentures that are convertible into common stock at $5.70 apiece; investors also were issued warrants to purchase an aggregate of 350,880 common shares for $6.17 each, and additional warrants to purchase an equal number of common shares for $6.71 apiece; SG Cowen Securities Corp. acted as the transaction's placement agent (2/26) |
|
||||
Martek Biosciences |
Credit facility |
N/A |
-- |
Martek closed a one-year, $10M secured working capital line of credit facility with Allfirst Bank (2/26) |
|
||||
Neose Technologies |
Private placement of common stock |
2.9S |
$17 |
Neose raised $17M in a private placement of 2.9M shares; Domain Associates LLC led the placement; undisclosed new and existing investors participated, and JPMorgan acted as the exclusive placement agent (2/17) |
|
||||
NexMed Inc. (NEXM) |
Exercise of warrants to purchase shares of common stock |
0.389W |
$0.533 |
NexMed raised $533,489 in interim financing through the exercise of 389,408 warrants to purchase shares of its common stock (2/6) |
|
||||
Novavax Inc. (NVAX) |
Private placement of common stock |
4.75S |
$16.6 |
Novavax raised about $16.6M through the private placement of 4.75M shares with SJ Strategic Investments LLC (2/18) |
|
||||
Nymox Pharmaceutical Corp. (NYMX) |
Private placement of common stock |
N/A |
$5 |
Nymox raised $5M in a private financing (2/25) |
|
||||
Onyx Pharmaceuticals Inc. (ONXX) |
Private placement of common stock |
2.1S |
$10 |
Onyx raised $10M through the private sale of about 2.1M shares; the shares were placed primarily with Deerfield Management Co. (2/18) |
|
||||
Ortec International Inc. (OTC BB: ORTC) |
Private placement of convertible preferred stock |
N/A |
$2 |
Ortec completed a $2M private placement of non-registered Series B convertible preferred stock; investors were Paul Capital Royalty Acquisition Fund LP and other previous investors (2/27) |
|
||||
Ribozyme Pharmaceuticals Inc. (RZYM) |
Private placement of common stock and warrants |
N/A |
$48 |
Ribozyme raised $48M in a private placement of stock and warrants with The Sprout Group, Venrock Associates, Oxford Bioscience Partners, Techno Venture Management and Granite Global Ventures (2/12) |
|
|
|||
SuperGen Inc. (SUPG) |
Private placement of notes and warrants |
W for 2S |
$21.25 |
SuperGen raised $21.25M in a private placement of senior exchangeable convertible notes and related warrants; the notes are convertible into SuperGen stock at $4.25 each; investors also received warrants to purchase nearly 2M shares (2/27) |
|
||||
Viventia Biotech Inc. (Canada; TSE:VBI) |
Private placement of units |
11.1U |
$2 |
Viventia raised $2M in a private placement of 11.1M units with Clairmark Investments (2/11) |
|
||||
|
| ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported. | ||||
OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||
